Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Work In Process (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Work In Process for 5 consecutive years, with $3.6 million as the latest value for Q3 2018.

  • On a quarterly basis, Work In Process rose 379.89% to $3.6 million in Q3 2018 year-over-year; TTM through Sep 2018 was $3.6 million, a 379.89% increase, with the full-year FY2017 number at $66000.0, down 97.49% from a year prior.
  • Work In Process was $3.6 million for Q3 2018 at Theravance Biopharma, up from $3.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.6 million in Q3 2018 to a low of $66000.0 in Q4 2017.
  • A 4-year average of $1.9 million and a median of $2.0 million in 2018 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: tumbled 97.49% in 2017, then surged 379.89% in 2018.
  • Theravance Biopharma's Work In Process stood at $145000.0 in 2014, then surged by 1711.72% to $2.6 million in 2016, then crashed by 97.49% to $66000.0 in 2017, then surged by 5396.97% to $3.6 million in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Work In Process are $3.6 million (Q3 2018), $3.3 million (Q2 2018), and $2.0 million (Q1 2018).